APOPTOSIS AND CANCER June 14-15, 2012 Downing College, University of Cambridge PROGRAMME Day 1 08:30 – 09:15 Registration 09:15 – 09:20 Welcome and Introductions Session 1 BCL2 family Session chair: Gerald Cohen 09:20 – 09:55 Jean Claude Martinou (University of Geneva, Switzerland) A novel function for the antiapoptotic Mcl-1 protein 09:55 – 10:30 David Andrews (McMaster University, Canada) Mechanisms of Mitochondrial Membrane Permeabilization by Pro-Apoptotic Bcl-2 Family Proteins 10:30 – 11:05 Meike Vogler (University of Leicester, UK) Identification of resistance pathways to BCL2 -inhibitors in leukemia cells 11 :05 – 11 :30 Morning Break 11:30 – 12:05 Anthony Letai (Dana-Farber Cancer Institute, US) Personalizing cancer therapy with mitochondrial BH3 profiling 12:05 – 12:25 Stefan Glaser (The Walter and Eliza Hall Institute, Australia) Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia 12:25 – 12:40 Abcam 12 :40 – 14:00 Lunch Sessio n 2 P53 family Session chair: David Wallach 14:00 – 14:35 Gerard Evan (University of Cambridge, UK) How to kill cancer cells 14:35 - 15:10 Karen Vousden (The Beatson Institute for Cancer Research, UK) The role of p53 in metabolic adaptation and survival 15:10 – 15:30 Martin Michaelis (University of Kent, UK) The MDM2 inhibitor nutlin-3 but not the p53 activator RITA induces loss of function p53 mutations 15:30 – 16:00 Afternoon Break 16:00 – 16:35 Gerry Melino (MRC Toxicology Unit, Leicester, UK) Involvement of p73, a p53-family member in metabolism and senescence 16:35 – 16:50 Jerome Kucharczak (CNRS, UCBL, ENS Lyon, France) Conversion of BFL-1 from protector to killer in tumor cells. Towards an original biotherapy for the treatment of blood cancers. 16:50 – 17:05 Selcuk Colak (AMC, The Netherlands) Inhibition of HDACs sensitizes chemotherapeutic resistant colon cancer stem cells 17:05 – 19 :00 Drinks Reception & Poster Session Day 2 Session 3 Death Receptors and Inflammation Session chair: Vishva Dixit 09:00 – 09:35 Henning Walczak (Imperial College London, UK) Linear ubiquitination in cell death, inflammation and immunity 09:35 – 10:10 David Wallach (Weizmann Institute of Science, Israel) Regulation of inflammation and cell-death trough interactions of RHIM-domain protein kinases with caspase-8 10 :10 – 10:40 Morning Break 10:40 – 11:15 Vishva Dixit (Genentech, US) The Inflammasome: What are the NOD sensors sensing? 11:15 – 11:30 Donia Moujalled (Walter and Eliza Institute of Medical Research, Australia) Mechanisms of RIPK3 induced cell death by TNF 11:30 – 11:45 Marion MacFarlane (MRC Toxicology Unit, Leicester, UK) The TRAIL Death-Inducing Signalling Complex – a new stoichiometry reveals novel structural insights 11:45 – 12:00 Rosalba Camicia (University of Zurich, Switzerland) B-aggressive lymphoma protein BAL1 mediates resistance to apoptosis and cell survival in diffuse large B-cell lymphoma (DLB-CLS ) 12 :00 – 13 :00 Lunch Session 4 IAP’s Session chair: Pascal Meier 13:00 – 13:35 Pascal Meier (Institute of Cancer Research, UK) IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer 13:35 – 13:50 Gianni Chessari (Astex Pharmaceuticals, UK) Discovery of a potent dual antagonist of both XIAP and cIAP1 using fragment based drug discovery 13:50 – 14:25 Domagoj Vucic (Genentech, US) IAP proteins: Ubiquitin ligases at the crossroads of apoptosis, inflammation and cancer 14 :25 – 14:50 Afternoon Break 14:50 – 15:25 Dale Porter (Novartis, US) Therapeutic targeting of IAPs 15:25 – 15:40 Meenu Perera (University of Maryland, US) Bax, Bcl-xL exert their regulation on different sites on the ceramide channel: implications on the ceramide pathway of apoptosis 15:40 – 16:15 Discussion – “Apoptosis and cancer - the next 10 years” Vishva Dixit, Dale Porter, Jean Claude Martinou, Anthony Letai, Gerard Evan 16 :15 Close .